License to heal

No items found.
​
September 7, 2021

The hallmark of 5G is extremely low latency speeds. In theory, robotics could be controlled from long distances with just 0.1 seconds of a delay.

In a medtech context, this means, for example, that a highly-skilled doctor in an economically developed country could perform remote surgery almost anywhere on Earth, provided the 5G infrastructure is in place.

Surgeons could react to a bleed with the kind of speed required when operating in real-time. It is not hard to imagine how this could benefit patients, for example, in less economically developed economies which do not have a comparable standard of health infrastructure or trained personnel.

Procedures of this type will require a major expansion in the existing 5G infrastructure.

One feature of 5G is that it requires many more base stations per square mile than previous generations of cellular technology. But the technical capabilities are there.

In 2019, Huawei, one of the world's leading providers of 5G technology, performed the first live experiment with 5G-enabled surgery on an animal.

A collaboration with a hospital in Fujian and a local robotics company, Huawei reported that the operation achieved "neat" surgical wounds with "no trace of blood in the whole process", while the animal's vital signs were stable following the procedure.

The possibilities for healthcare do not end there. The automotive industry, another sector that has engaged with the potential of 5G perhaps more than any other, is developing driverless vehicles. And the benefits of this work will not just be limited to consumer cars. We may also see 5G-connected ambulances, which have already been the subject of extensive research.

In Milan, Vodafone has been trialling the use of 5G to connect ambulances with hospitals, offering a higher standard of care than previously thought possible.

5G can allow paramedics to send 360° images to hospitals in real time, and instantly review patients' medical histories. It could also transform the scale of care that can be offered in an ambulance before a patient reaches the hospital.

Using emerging technologies such as artificial intelligence and augmented reality (AR), powered by 5G's low-latency speeds, doctors can instruct paramedics on performing operations which normally would require a patient to be present in the hospital.

Similar trials carried out in the UK by Ericsson, King's College London, and the National Health Service allowed clinicians to perform surgery remotely using an AR headset and a joystick.

The rest of this article is available to download as part of our ‘what's next for medtech' whitepaper. Download for free here.

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Beyond protection: Turning patent portfolios into commercial advantage
12 November 2026
A strong patent portfolio should do more than protect innovation. It should support the wider commercial ambitions of the business. This article explores how businesses can move beyond simply accumulating patents and instead build portfolios that create genuine commercial value. From aligning filing decisions with products and markets to supporting investment, licensing and partnerships, it considers how a focused patent strategy can strengthen competitive advantage while ensuring every right continues to earn its place.
#
Consulting
​
Samsung v ZTE: Will multiple rate setting trials become more common?
12 November 2026
The Samsung v ZTE dispute has highlighted the growing potential for multiple courts to determine FRAND rates within the same licensing dispute. This article explores how approaches in the UK, China and potentially the UPC could shape future FRAND litigation, the challenges posed by competing rate determinations, and whether arbitration could offer an alternative route to resolution.
#
Litigation
​
FRAND rate setting at the UPC: an emerging route for SEP owners?
10 November 2026
The UPC could be emerging as an important new forum for FRAND rate setting. Drawing on recent patentee-led actions and judicial commentary, this article explores how SEP owners might seek a UPC determination of FRAND terms and what this developing approach could mean for European enforcement and licensing strategies.
#
Litigation
​
Getting technical: Lessons from the emotional perception Remittal
28 October 2026
The Emotional Perception patent application has been refused again following its remittal to the UKIPO. The decision illustrates that clearing the relatively low threshold to qualify as an invention is only the first hurdle. For AI and other computer-implemented inventions, the crucial question is which features contribute to a technical solution to a technical problem and can therefore support inventive step.
#
Consulting
​
Quantum IP strategy: Own control points, not patent counts
14 October 2026
In quantum, the strongest portfolios will not be the biggest. Stuart Malcolm sets out six moves for owning the control points the market cannot route around, and the questions investors will ask.
#
Consulting
​
Targeted, not transformative: The UKIPO’s considered course on SEPs
13 October 2026
Andrew Sharples analyses the UKIPO's response to its SEP consultation, exploring proposed changes to FRAND dispute resolution, SEP transparency and licensing guidance, and what they mean for SEP holders and implementers.
#
Consulting
​
Chinese companies in European patent litigation
30 September 2026
Chinese companies are becoming increasingly active in European patent litigation, both as defendants and as patent owners enforcing their own rights. This article examines the growing role of Europe and the Unified Patent Court (UPC) in global patent disputes, highlighting key cases involving Chinese businesses and the strategic opportunities and risks that come with operating in European markets. It is the first in a series exploring the practical implications of European patent enforcement for Chinese companies.
#
Patenting
​
How to mitigate prior art traps for follow-on pharma patents
27 August 2026
Follow-on patents are increasingly important for pharmaceutical innovators. Learn how new EMA clinical trial disclosure rules create prior art risks and discover practical strategies to protect pharmaceutical IP and maximise patent value.
#
Consulting
​
Chinese companies and the UPC: from enforcement targets to strategic users
13 August 2026
Chinese companies are playing an increasingly significant role in UPC litigation, accounting for around 38% of infringement actions in 2025. While many remain defendants, a growing number are actively using the Unified Patent Court to enforce their own patent rights across Europe. The trend highlights the UPC's rising importance for Chinese businesses operating in sectors such as telecommunications, semiconductors, medical devices and renewable energy, and signals a shift in global patent enforcement strategy.
#
Patenting
​
Evaluating the environmental impact of patent AI.
31 July 2026
AI's environmental impact is rarely out of the headlines, but how does it compare to the benefits it delivers in practice? In this article, Laurence Brown examines the energy use of AI-assisted patent drafting, comparing it with traditional drafting workflows. While measuring AI's true environmental footprint is far from straightforward, the analysis suggests that AI-assisted patent drafting may already be more energy efficient, while delivering significant productivity gains for patent professionals.
#
Patenting
​
UPC appeals after three years: Early indications on appeal success rates
15 July 2026
Three years into the UPC, appeal overturn rates sit at 56% for both substantive and preliminary injunction cases, with Kodak v Fujifilm among the rulings reshaping outcomes on appeal.
#
Litigation
​
The UPC after three years: From experiment to enforcement forum
15 July 2026
1,282 cases filed at the UPC in three years: infringement actions have surged while revocation filings stayed flat, easing fears the Court would become a European patent graveyard.
#
Litigation
​
Podcast: Building an AI-Native law firm
26 June 2026
On the Technically Legal podcast, EIP partner Laurence Brown discusses how Visser AI is redesigning patent workflows, letting the firm offer fixed fees without trading away speed or quality.
#
Patenting
​
Choosing your SEP battleground: UPC, Germany or UK?
07 June 2026
Choosing the right venue for SEP litigation can significantly influence the outcome of FRAND disputes. This article compares the UPC, German and UK courts, examining their approaches to injunctions, FRAND defences, rate-setting and enforcement. It highlights the strategic advantages of each jurisdiction and explains why many SEP owners are increasingly turning to the UK and UPC as part of their European enforcement strategy.
#
Litigation
​
Synthetic Lethality & AI: IP Strategy in Oncology
26 May 2026
This article explores the resurgence of synthetic lethality in precision oncology, highlighting how AI and machine learning are accelerating the discovery of new therapeutic targets. It also examines growing clinical activity, investment, and the evolving intellectual property challenges shaping this emerging field.
#
Consulting
​